Director Daniel S Janney Files Intent to Sell Additional $3.7M in Krystal Biotech Stock After Recent $10.1M Sale
KRYS has more than doubled off its 52-week low of $122.8.
Summary
Director Daniel S Janney has filed an intent to sell an additional $3.7 million in Krystal Biotech shares, following a recent sale of $10.1 million, indicating significant insider selling.
Key Events · Ownership and Investor Activity · KRYS
-
Director Files Intent to Sell
Daniel S Janney, a Director, filed a Form 144 indicating intent to sell 13,825 shares of common stock, valued at approximately $3.7 million.
-
Recent Significant Share Sale
The filing also reports that Daniel S Janney recently sold 37,895 shares, generating gross proceeds of approximately $10.1 million.
-
Cumulative Insider Selling
This intent to sell, combined with the recent sale, represents over $13.8 million in selling activity by a director, contributing to a pattern of insider distribution.
Analysis · KRYS · Life Sciences
This Form 144 filing indicates that Director Daniel S Janney intends to sell 13,825 shares of Krystal Biotech common stock, valued at approximately $3.7 million. This follows a reported sale of 37,895 shares by Janney, generating $10.1 million in gross proceeds, as disclosed within the same filing. The cumulative selling activity by a director, totaling over $13.8 million, signals a significant reduction in insider holdings and contributes to a broader pattern of insider distribution observed in recent months. Investors should monitor further insider transactions for continued sentiment.
At the time of this filing, KRYS was trading at $266.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $122.80 to $298.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.